BP
NVO

Ballentine Partners’s Novo Nordisk NVO Stock Holding History

Ballentine Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.9M Buy
39,607
+2,821
+8% +$121K 0.02% 233
2026
Q1 		$1.35M Buy
36,786
+8,894
+32% +$421K 0.02% 284
2025
Q4 		$1.42M Sell
27,892
-907
-3% -$46.4K 0.02% 254
2025
Q3 		$1.6M Sell
28,799
-6,830
-19% -$400K 0.02% 239
2025
Q2 		$2.46M Buy
35,629
+6,801
+24% +$463K 0.04% 166
2025
Q1 		$2M Buy
28,828
+239
+0.8% +$19.7K 0.03% 185
2024
Q4 		$2.46M Buy
28,589
+1,854
+7% +$200K 0.04% 148
2024
Q3 		$3.18M Buy
26,735
+903
+3% +$120K 0.05% 120
2024
Q2 		$3.69M Buy
25,832
+2,217
+9% +$294K 0.07% 101
2024
Q1 		$3.03M Buy
23,615
+2,728
+13% +$325K 0.06% 109
2023
Q4 		$2.16M Buy
20,887
+3,409
+20% +$337K 0.04% 136
2023
Q3 		$1.59M Buy
17,478
+224
+1% +$19.7K 0.04% 142
2023
Q2 		$1.4M Buy
17,254
+3,354
+24% +$274K 0.03% 157
2023
Q1 		$1.11M Buy
13,900
+274
+2% +$19.4K 0.03% 185
2022
Q4 		$922K Sell
13,626
-1,368
-9% -$80.2K 0.03% 177
2022
Q3 		$746K Buy
14,994
+352
+2% +$18.9K 0.03% 187
2022
Q2 		$816K Buy
14,642
+1,346
+10% +$74.7K 0.03% 175
2022
Q1 		$738K Sell
13,296
-148
-1% -$7.6K 0.02% 209
2021
Q4 		$753K Sell
13,444
-264
-2% -$14.3K 0.02% 213
2021
Q3 		$658K Sell
13,708
-3,502
-20% -$169K 0.02% 200
2021
Q2 		$720K Buy
17,210
+154
+0.9% +$5.97K 0.02% 188
2021
Q1 		$575K Buy
17,056
+134
+0.8% +$4.77K 0.02% 208
2020
Q4 		$591K Sell
16,922
-34
-0.2% -$1.18K 0.02% 194
2020
Q3 		$588K Sell
16,956
-200
-1% -$6.67K 0.03% 190
2020
Q2 		$562K Sell
17,156
-376
-2% -$12K 0.03% 198
2020
Q1 		$527K Buy
17,532
+282
+2% +$8.4K 0.03% 185
2019
Q4 		$499K Buy
17,250
+676
+4% +$18.7K 0.02% 227
2019
Q3 		$429K Sell
16,574
-268
-2% -$6.78K 0.02% 231
2019
Q2 		$430K Buy
16,842
+2,402
+17% +$59.4K 0.02% 233
2019
Q1 		$378K Buy
14,440
+484
+3% +$11.9K 0.02% 220
2018
Q4 		$321K Sell
13,956
-200
-1% -$4.44K 0.02% 231
2018
Q3 		$333K Sell
14,156
-28
-0.2% -$683 0.02% 254
2018
Q2 		$327K Sell
14,184
-448
-3% -$10.6K 0.02% 244
2018
Q1 		$360K Buy
14,632
+3,680
+34% +$96.6K 0.02% 234
2017
Q4 		$293K Buy
10,952
+1,368
+14% +$34.8K 0.02% 268
2017
Q3 		$231K Sell
9,584
-1,016
-10% -$23K 0.01% 321
2017
Q2 		$216K Buy
+10,600
New +$214K 0.02% 335
2017
Q1 		– Sell
-17,598
Closed -$420K – 276
2016
Q4 		$420K Buy
+17,598
New +$319K 0.03% 125
2016
Q3 		– Sell
-15,818
Closed -$425K – 225
2016
Q2 		$425K Buy
15,818
+284
+2% +$7.79K 0.04% 122
2016
Q1 		$421K Buy
+15,534
New +$416K 0.04% 122

Other funds holding NVO

SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
ONB
Old National Bancorp Evansville, Indiana $5.02B AUM 25.65% 1-Year Est. Return
VFM
Viking Fund Management Minot, North Dakota $1.12B AUM 44.65% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
ERP
Eldred Rock Partners San Antonio, Texas $465M AUM 48.86% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return

Ballentine Partners's NVO Position: Q2 2026 in Review

Ballentine Partners increased its Novo Nordisk (NVO) stake by 7.7% in Q2 2026, buying an estimated $121K and bringing the position to 39,607 shares worth $1.9M. The position accounts for 0.02% of the portfolio, ranked #233.

Ballentine Partners first reported a position in NVO in Q1 2016 and has held it in 40 quarters since. The position peaked at $3.69M in Q2 2024. 205 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Ballentine Partners held 39,607 shares of Novo Nordisk worth $1.9M as of Q2 2026.
  • Ballentine Partners bought 2,821 Novo Nordisk shares in Q2 2026, an estimated $121K.
  • Novo Nordisk made up 0.02% of Ballentine Partners's portfolio in Q2 2026, its #233 holding.
  • Ballentine Partners first reported a position in Novo Nordisk in Q1 2016 and has held it in 40 quarters since.
  • Ballentine Partners's Novo Nordisk position peaked at $3.69M in Q2 2024.
  • 205 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.